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Abstract
Introduction: Healthy body weight is an important factor for prevention of breast cancer recurrence. Yet, weight
loss and weight gain are not currently included in clinical-practice guidelines for posttreatment of breast cancer.
The work reported addresses one of the questions that must be considered in recommending weight loss to
patients: does it matter what diet plan is used, a question of particular importance because breast cancer
treatment can increase risk for cardiovascular disease.
Methods: Women who completed treatment for breast cancer were enrolled in a nonrandomized, controlled
study investigating effects of weight loss achieved by using two dietary patterns at the extremes of macronutrient
composition, although both diet arms were equivalent in protein: high fat, low carbohydrate versus low fat, high
carbohydrate. A nonintervention group served as the control arm; women were assigned to intervention arms
based on dietary preferences. During the 6-month weight-loss program, which was menu and recipe defined,
participants had monthly clinical visits at which anthropometric data were collected and fasting blood was
obtained for safety monitoring for plasma lipid profiles and fasting glucose. Results from 142 participants are
reported.
Results: Adverse effects on fasting blood lipids or glucose were not observed in either dietary arm. A decrease in
fasting glucose was observed with progressive weight loss and was greater in participants who lost more weight,
but the effect was not statistically significant, even though it was observed across both diet groups (P = 0.21).
Beneficial effects of weight loss on cholesterol (4.7%; P = 0.001), triglycerides (21.8%; P = 0.01), and low-density
lipoprotein (LDL) cholesterol (5.8%; P = 0.06) were observed in both groups. For cholesterol (P = 0.07) and LDL
cholesterol (P = 0.13), greater reduction trends were seen on the low-fat diet pattern; whereas, for triglycerides (P =
0.01) and high-density lipoprotein (HDL) cholesterol (P = 0.08), a decrease or increase, respectively, was greater on
the low-carbohydrate diet pattern.
Conclusions: Because an individual’s dietary preferences can affect dietary adherence and weight-loss success, the
lack of evidence of a negative effect of dietary pattern on biomarkers associated with cardiovascular risk is an
important consideration in the development of breast cancer practice guidelines for physicians who recommend
that their patients lose weight. Whether dietary pattern affects biomarkers that predict long-term survival is a
primary question in this ongoing clinical trial.
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Introduction
A lifestyle change can halve the risk of breast cancer
recurrence and reduce the risk of breast cancer-asso-
ciated mortality by one third. However, many clinicians
do not recommend this strategy to their patients. The
simple course of action, which generally is not dis-
cussed, is promoting a healthy weight, and for many
individuals, this means weight loss. In this article, we
begin to address this dormant opportunity in the clinical
management of breast cancer with the goal of stimulat-
ing interest in generating the scientific evidence base
required for considering weight management in clinical
practice guidelines for the long-term survival of breast
cancer patients.
A number of reports indicate that the prognosis for
long-term survival after treatment for breast cancer is
better in women who have a body weight for height,
assessed by body mass index (BMI, body weight (kg)/
(height (m))2), that is considered to be in the normal
range (BMI, 18.5 to 24.9) versus women who are over-
weight (BMI, 25.0 to 29.9) or obese (BMI, ≥ 30.0)
[1-11]. Consistent with those reports is the observation
that weight gain after diagnosis increases risk for breast
cancer recurrence, whereas weight loss in breast cancer
survivors improves the chances of long-term survival
[12,13]. If one takes the available epidemiologic and
clinical data at face value, it prompts the question, why
is relatively little attention paid to weight control in the
clinical management of breast cancer after treatment.
Overweight and obesity are common problems in the
United States, and little evidence indicates that preva-
lence is less in breast cancer survivors than in the popu-
lation at large, which is estimated to be more than 60%
[14-16]. Thus, given that the majority of breast-cancer
survivors have excess weight as a risk factor, the popula-
tion at risk is large. However, a number of challenges
are faced by the physician. They include issues such as
initiating a conversation about weight loss while recog-
nizing the sensitivity of the subject and time constraints
on office visits, which do not allow sufficient time to
address the complexity of weight-management issues for
each patient, including the knowledge and behavioral
gaps related to diet and weight loss. Moreover, doctors
may hesitate to emphasize weight loss, given the recog-
nized 95% long-term failure rates of most weight-control
efforts, making this information less a priority during
the office visit (15-18). Additionally, because of lack of
knowledge about the subject matter, basic questions
such as “how should weight loss be achieved?” and “how
much weight loss will provide benefit?” cannot be
answered with confidence.
Although many studies have been reported about dif-
ferences in effectiveness among various approaches to
weight loss [17-25], relatively few studies have been con-
ducted in a free-living population of breast-cancer survi-
vors in the private-practice setting. The focus of this
article is on whether diets that are the extremes of what
most patients adopt for weight loss have any obvious
deleterious effects in this population. Although treat-
ment for breast cancer continues to improve, some first-
line approaches still involve the use of agents with cardi-
otoxic potential [26-28]. Consequently, concern exists
about cardiovascular risk factors and survival implica-
tions after breast-cancer treatment. This situation pro-
vided the rationale for the analysis of the blood-lipid
profile, widely used for monitoring cardiovascular dis-
ease risk, and fasting glucose as an early indicator of
insulin resistance, which were collected as a safety com-
ponent of the investigation of the effects of diet compo-
sition and weight loss on biomarkers of long-term
survival in breast-cancer patients after treatment.
For the analyses reported, magnitude of weight loss
was dichotomized as being greater or less than the
mean weight loss of the study population. This was
done to address whether all participants are affected
similarly or if the blood-biomarker outcomes are depen-
dent on the magnitude of weight loss.
Materials and methods
Subjects
Women recruited for participation were from the same
oncology practice and were at least 4 months after che-
motherapy, radiation, and surgical treatment for breast
cancer and considered clinically free of cancer. Accrual
occurred from 2008 to 2010. Participants were referred
by their medical oncologist and had a BMI in the over-
weight or obese class I range (BMI, 25 to 34.9 kg/m2).
Eligibility
To be eligible, participants did not anticipate surgery
over the study duration period; did not follow a special
diet excluding foods or food groups; had not lost 4 or
more pounds of body weight over the month preceding
study initiation; did not take pharmaceuticals or supple-
ments for weight management; were not being treated
for diabetes or blood-glucose control; had no history of
eating disorders; did not have digestive issues that might
interfere with dietary intake, such as irritable bowel syn-
drome, Crohn disease, or diverticulitis; never had sur-
gery involving constriction or removal of any portion of
the gastrointestinal tract; had not been diagnosed with
hepatitis B, C, or HIV; did not have implanted electronic
devices such as a pacemaker; and did not use tobacco
products. Participants also had to be willing to follow a
dietary plan prescribed for the duration of the study;
adhere to American Cancer Society alcohol guidelines
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(one or fewer standard drinks per day); maintain or
increase physical activity as prescribed to achieve nega-
tive energy balance required for 0.5 to 1.0 kg weight
loss per week; wear a pedometer and record daily activ-
ity; wear an accelerometer/heart-rate monitor for 2
weeks during the study; wear a body or swim suit and
cap for body-composition testing; record food intake
daily; attend up to 10 one-on-one clinic visits and five
group visits over a 27-week period, and provide seven
fasting blood samples and 3-day pooled urine samples.
Study design
This study, referred to as CHOICE, compares the effects
of opposing dietary patterns (carbohydrate and fat con-
tent at opposite extremes of popular weight-loss diet
composition) on weight loss and body composition
changes, as well as effects on biomarkers of metabolic
and hormonal processes known to affect breast carcino-
genesis and that are predictive of long-term survival.
The details of the CHOICE research protocol have been
published[29]. The data reported herein were collected
as part of safety monitoring in a study designed as a
nonrandomized, controlled trial. Assignment to treat-
ment arm was based on dietary preferences because
patient motivation is critical to successful weight loss,
and dietary preferences can be strong determinants of
adherence to a dietary plan. Participants were followed
up for 6 months. During the course of the study, the
withdrawal rate was 9.4% for the nonintervention con-
trol group, 12.9% for the low-carbohydrate group, and
11.3% for the low-fat group.
Demographic data and usual food intake via food-fre-
quency questionnaire (VioFFQ; Viocare, Princeton, NJ)
were collected at baseline. At the initiation of the study
and at 4-week intervals thereafter, up to 6 months,
anthropometry including weight, waist-to-hip ratio,
BMI, body composition (BOD POD; Life Measurement,
Inc., Concord, CA), and bioelectrical impedance (Tanita
Corporation of America, Arlington Heights, IL) were
obtained. Blood samples were obtained to assess cardio-
vascular-risk markers. These measures were assessed
and compared at baseline and at 6 months in the con-
trol group. The clinical protocol was approved by the
Institutional Committee for the Protection of Human




Individuals not interested in joining the weight-loss
arms of the study but who wished to participate were
assigned to the nonintervention control group and were
given the same information currently provided to all
breast-cancer patients about the importance of avoiding
posttreatment weight gain, and the health benefits of
having a BMI in the normal range.
Intervention
Intervention participants follow a structured diet/physi-
cal activity program designed to create a weekly negative
energy balance equivalent to 3, 500 kcal, after adjust-
ments for metabolic adaptations that occur during
extended periods of weight loss. The intervention
groups received the same physical-activity protocol pro-
moting the physical-activity guidelines and translated
into step recommendations, but one of two diets that
reflect commonly used weight-loss approaches that were
identified in women attending a private oncology prac-
tice for long-term breast-cancer follow-up.
The diet plan for each group comprised a 28-day cycle
of menus and recipes. The ingredients for each day’s diet
plan were entered into ProNutra Diet Analysis software.
The macronutrient composition of the 28-day menu plan
is shown in Table 1. The intended diet composition was
derived from (a) identifying the most popular weight-loss
Table 1 Dietary composition by diet group for a 28-day menu cycle (1, 200 kcal/day)
Low carbohydrate, high fat High carbohydrate, low fat
Calories 1, 204 ± 35 1, 186 ± 58












Fiber (g) 17 ± 4 26 ± 5
Sodium (mg) 2, 113 ± 741 2, 586 ± 688
Cholesterol (mg) 244 ± 131 120 ± 85
Saturated fat (g) 11 ± 2 5 ± 2
Monounsaturated fat (g) 21 ± 3 5 ± 1
Polyunsaturated fat (g) 9 ± 2 5 ± 1
S/M/P ratio 1:2:1 1:1:1
Values are expressed as calories, grams, or milligrams ± standard deviation. Values in parentheses are percentage of energy ± standard deviation. Cycle menus
were developed for the following calorie levels: 1, 200, 1, 400, 1, 600, and 1, 800 kcal/d.
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programs undertaken by the clinic breast-cancer popula-
tion; (b) conducting a systematic review of the literature to
define the macronutrient composition of these diets and
the actual intakes during weight-loss studies to determine
feasible upper and lower limits; (c) defining an acceptable
overlap that ensured diet separation (< 5% for fat and car-
bohydrate). The 28-day meal plans were designed for five
calorie levels in each diet arm. The meal plans included
interchangeable meal options (home-prepared recipes and
meal instructions; eating out; and convenience meal
options), educational material and a program incorporat-
ing weight-loss strategies based on a systematic review of
those that support successful weight loss and maintenance
and promote high levels of dietary adherence. The inter-
vention was designed to reflect a feeding study in free-liv-
ing individuals, where strict dietary structure is presented
in a format that also offers enough flexibility to be adopted
into daily living and by the families and social-support net-
works of participants.
Laboratory measurements
Laboratory analyses were performed by Quest Diagnos-
tics Inc. Fasting glucose was measured by using the hex-
okinase/glucose-6-phosphate dehydrogenase method
with spectrophotometry [30]. Total cholesterol, HDL
cholesterol, and triglyceride in plasma were determined
enzymatically. For HDL, serum was combined with the
20% wt/vol polyethylene glycol in glycine buffer at pH
10.0 (25°C). All b-lipoproteins (LDL and VLDL) were
precipitated. The HDL fraction (a-fraction) remained in
the supernatant. The supernatant was then treated as a
sample and assayed for cholesterol by an enzymatic
method to determine HDL cholesterol value. Plasma
LDL cholesterol was calculated by using following for-
mula: LDL cholesterol = total cholesterol - (HDL cho-
lesterol + (triglyceride/5)) [30-34].
Statistical methods
Cohort characteristics at baseline were described as
mean ± SD, and differences across diet groups were
evaluated by using the global F test in a one-way analy-
sis of variance. Maximum likelihood (ML) estimates of a
repeated-measures model [35] by using complete cases
were developed to assess the change over time in lipid
measures; in other words, these were not intent-to-treat
analyses. Separate slopes were estimated for diet group,
and successful weight loss, defined as above or below
the overall average weight loss in the two diet groups;
that is, five slopes were present: control, high carbohy-
drate with weight loss greater than average, high carbo-
hydrate with weight loss less than average, high fat with
weight loss greater than average, and high fat with
weight loss less than average. Linear contrasts were used
to evaluate differences between selected slopes. Because
visits were scheduled at roughly 1-month intervals, the
slopes can be interpreted as the observed average
change in a given measure for 1 month on treatment;
the 6-month change can be estimated by multiplication.
SAS version 9.2 (SAS Institute Inc., Cary, NC) was used
for all statistical analyses. The Hochberg step-up proce-
dure was use to adjust for multiple comparisons within
each marker [36]. The algorithm is sort the P values
from largest to smallest [37]: (k) , P(k-1) , ..., P(1)
p˜(k) = p(k)
p˜(k−1) = min(p˜(k), 2p(k−1)).
...
p˜(1) = min(p˜(2), kp(1)).
The adjustments are valid whether test statistics are
independent or positively correlated.
Results and Discussion
The effect of dietary pattern on blood-lipid and -glucose
profiles was evaluated in 142 study participants. Data at
baseline for the participants are shown in Table 2. No
differences among groups were found in age, BMI, body
weight, fat mass, disease stage, type of chemotherapy or
hormonal therapy received, use of statins, or among the
blood chemistries that served as end points in this
investigation. To determine whether magnitude of
weight loss had a moderating effect on the blood-lipid
profile in the diet, the active treatment arms were subdi-
vided into two groups corresponding to patients above
or below the mean weight loss, which was 10 kg during
the 6-month program. In brief, the range in weight loss
over a 6-month period for the low-fat dietary group was
3.5 to 18.9 kg, and the range in body-fat loss was 3.4 to
19.3 kg. For the low-carbohydrate dietary group, the
range in weight loss was 2.1 to 17.2 kg, and the range in
body-fat loss was 1.2 to 18.5 kg. Based on self-reported
pedometer counts, participants following the low-fat
diet plan recorded 9, 661 ± 162 steps per day versus 8,
741 ± 170 steps per day for participants following the
low-carbohydrate diet plan (mean ± SEM, P < 0.05).
The research protocol involved monthly clinical visits
during which fasting blood was drawn, and anthropo-
metric data were collected. Blood was sent to the clini-
cal laboratory routinely used by the office practice in
which the weight management facility is located to base
analysis and interpretation of results on the same source
of data routinely used by the attending physicians. The
detailed data from each clinic visit throughout the
course of the study for each subgroup are shown in
Table 3. Although inspection of those data is useful, it
was decided that data interpretation would be facilitated
by performing regression analyses of the entire set of
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data for each participant for each variable assessed. For
ease of understanding, a representative regression is
shown in the Figure 1, with a detailed explanation of
the data resulting from the regression analysis provided
in the figure legend. The regression coefficients for all
plasma analytes evaluated are summarized in Table 4,
which also contains the statistical results.
Fasting blood glucose was assessed because elevations
in this parameter can be an early indicator of developing
insulin resistance, which is a risk factor for cardiovascu-
lar disease [38,39]; data on insulin, which are necessary
for the computation of HOMA-IR, were not collected as
part of safety monitoring, and therefore, further assess-
ment is not possible at this time. The regression coeffi-
cients are negative for all weight-loss subgroups
investigated. This means that fasting glucose decreased
with progressive weight loss. The effect of weight loss
was more pronounced than the effect of diet, although
neither was statistically significant. The magnitude of
the decrease in fasting glucose over time (slope of the
line) was somewhat greater in participants who lost
more weight when data were collapsed across diet
groups: the difference in slopes was -0.46 ± 0.24 (P =
0.21). Similarly, the magnitude of the decrease in fasting
glucose over time was somewhat greater in the low-fat
arm than in the low-carbohydrate arm when data were
collapsed across weight-loss groups: the difference in
slopes was -0.31 ± 0.24 (P = 0.21). These findings are
notable for several reasons. First, widespread debate is
ongoing about the potential for high-fat diets to pro-
mote atherogenesis through the induction of insulin
resistance, which can lead to elevated fasting glucose
[25]. Second, relative to creating a microenvironment
conducive to tumor growth, a repeated emergence of
attention is noted in the metabolic re-programming that
accompanies the development of cancer and recognition
of the preference of many carcinomas for glucose or
glutamine, which is actively taken up from the vascular
system [40-44]. Hence, concern exists that diets rich in
carbohydrates with a high glycemic load would stimulate
tumor growth [45,46]. In the context of weight loss, no
evidence was obtained to support either concern, as
reflected by fasting glucose determined monthly over a
period of 6 months; however, the differences between
the slopes on diet averaged over weight were smaller (P
= 0.06) than the differences between weight-loss groups
averaged over diet (P = 0.21). This finding is consistent
with the importance of weight loss to attain a body
weight in the target range for height, which is generally
stated as a body mass index (BMI, body weight in kilo-
grams/height in square meters) between 18.5 and 24.9,
although the target range can vary based on race [47].









Age (years) 56.61 ± 7.73 56.32 ± 8.08 55.19 ± 8.09 0.66
BMI 29.13 ± 2.92 28.37 ± 2.43 29.47 ± 2.65 0.12
Weight (lb) 175.53 ± 22.25 172.11 ± 18.54 176.74 ± 20.17 0.51
% Fat mass 43.37 ± 5.63 42.31 ± 4.91 43.65 ± 4.86 0.39
Glucose 83.60 ± 8.46 83.40 ± 9.22 86.33 ± 6.87 0.16
Cholesterol 204.72 ± 31.55 204.08 ± 42.41 201.66 ± 31.92 0.91
Triglycerides 133.28 ± 53.96 113.54 ± 58.72 139.13 ± 69.48 0.10
HDL 59.49 ± 16.10 66.30 ± 18.56 61.28 ± 15.87 0.13
LDL 118.53 ± 29.76 115.12 ± 37.56 112.57 ± 28.99 0.69
Chol/HDL ratio 3.63 ± 0.97 3.28 ± 1.05 3.50 ± 1.08 0.25
Years since diagnosis 5.43 ± 4.09 6.78 ± 6.21 8.40 ± 5.80 0.037
Stage 0 (%) 9.1 12.0 4.2 0.38
Stage I (%) 38.6 34.0 43.8 0.62
Stage IIA (%) 22.7 28.0 27.1 0.73
Stage IIB (%) 15.9 18.0 10.4 0.56
Stage IIIA (%) 9.1 4.0 6.3 0.61
Stage IIIB (%) 4.5 4.0 4.2 0.33
Stage IIIC (%) 0.0 0.0 2.1 0.41
Chemotherapy (%) 56.8 70.0 62.5 0.41
Hormonal therapy (%) 77.3 82.0 77.1 0.80
Statins (%) 15.9 18.0 20.8 0.83
Other cholesterol-lowering
agents (%)
2.3 2.0 2.1 0.33
Carb, carbohydrate; HDL, high-density lipoprotein; LDL, low-density lipoprotein. Values are expressed as mean ± standard deviation.
Thompson et al. Breast Cancer Research 2012, 14:R1
http://breast-cancer-research.com/content/14/1/R1
Page 5 of 9
Table 4 also shows the regression coefficients (estimated
slopes) for plasma cholesterol, triglycerides, HDL choles-
terol, and LDL cholesterol. These lipid and lipoprotein
analytes are routinely used to monitor cardiovascular
disease risk, but emerging evidence also indicates their
potential relevance to tumor growth and progression [48].
A beneficial change in cholesterol, triglyceride, or LDL
cholesterol is indicated by a negative regression coefficient,
Table 3 Mean levels of biomarkers over time by diet group
Month 0 1 2 3 4 5 6
Glucose
Control 83 ± 1.3 - - - - - 84 ± 1.2
Low fat 83 ± 1.2 80 ± 1.1 82 ± 1.1 80 ± 1.0 79 ± 1.0 80 ± 1.1 80 ± 1.1
Low carb 86 ± 1.2 84 ± 1.1 83 ± 1.1 83 ± 1.0 82 ± 1.2 83 ± 1.1 82 ± 1.1
Cholesterol
Control 205 ± 5.4 - - - - - 205 ± 5.4
Low fat 204 ± 5.1 178 ± 5.0 183 ± 4.9 187 ± 4.9 189 ± 4.9 189 ± 5.2 192 ± 5.2
Low carb 201 ± 5.2 184 ± 5.1 191 ± 5.0 193 ± 5.0 192 ± 5.0 194 ± 5.3 194 ± 5.3
Triglyceride
Control 131 ± 9.3 - - - - - 126 ± 7.5
Low fat 114 ± 8.7 104 ± 6.9 105 ± 8.0 108 ± 7.0 99 ± 6.7 100 ± 7.0 100 ± 6.6
Low carb 138 ± 8.9 100 ± 7.0 112 ± 8.2 100 ± 7.2 100 ± 6.9 102 ± 7.1 97 ± 6.7
HDL
Control 60 ± 2.6 - - - - - 60 ± 2.2
Low fat 66 ± 2.4 58 ± 2.0 60 ± 2.1 61 ± 2.3 64 ± 2.3 64 ± 2.2 66 ± 2.3
Low carb 61 ± 2.5 59 ± 2.0 60 ± 2.1 62 ± 2.4 63 ± 2.4 64 ± 2.3 65 ± 2.4
LDL
Control 118 ± 4.9 - - - - - 118.93 ± 4.88
Low fat 115 ± 4.6 98 ± 4.5 103 ± 4.4 105 ± 4.3 106 ± 4.6 105 ± 4.8 106 ± 5.0
Low carb 112 ± 4.7 105 ± 4.6 108 ± 4.5 111 ± 4.4 108 ± 4.7 110 ± 4.8 108 ± 5.12
CHOL/HDL
Control 3.62 ± 0.16 - - - - - 3.56 ± 0.13
Low fat 3.28 ± 0.15 3.19 ± 0.12 3.21 ± 0.12 3.26 ± 0.13 3.16 ± 0.13 3.10 ± 0.13 3.09 ± 0.13
Low carb 3.50 ± 0.15 3.24 ± 0.13 3.34 ± 0.13 3.26 ± 0.13 3.16 ± 0.13 3.17 ± 0.13 3.07 ± 0.13
Carb, carbohydrate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Figure 1 Effect of weight loss and diet on plasma triglycerides. Estimated slopes for predicted triglycerides (TGs) based on a repeated-
measures model by group and whether weight loss was below or above the mean for the study population. Slope is the estimated monthly
change in TGs. All slopes are significantly different from 0, with the exception of the control group. The Hochberg step-up procedure was used
to adjust P values for multiple comparisons within each marker. Averaging over diet, the high- versus low-weight-loss slopes are different from
each other (P = 0.01); with averaging over weight loss, the low-fat versus low-carbohydrate slopes are different from each other (P = 0.01), and
within the low-carbohydrate diet, the high-weight-loss slope is significantly different from the low-weight-loss slope (P = 0.01). LFLWL, Low-fat
low weight loss; LFHWL, low-fat high weight loss; LCLWL, low-carbohydrate low weight loss; LCHWL, low-carbohydrate high weight loss.
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whereas higher levels of HDL cholesterol, indicated by a
positive regression coefficient, are desirable for cardiovas-
cular disease risk, although this may not be the case for
cancer. The data in Table 4 show beneficial effects of
weight loss on all four lipid analytes, as well as the ratio of
cholesterol to HDL cholesterol. The degree of benefit was
significantly greater for cholesterol (P = 0.001), triglycer-
ides (P = 0.01), and LDL cholesterol (P = 0.06) in indivi-
duals who lost more than 10 kg versus those individuals
who were less successful. A more-detailed inspection of
the regression coefficients reveals that overall (irrespective
of whether weight loss was below or above the mean), dif-
ferential effects on the lipid analytes were found, depend-
ing on dietary assignment. For cholesterol (P = 0.07) and
LDL cholesterol (P = 0.13), greater reductions appeared
on the high-carbohydrate diet pattern; whereas, for trigly-
cerides (P = 0.01) and HDL cholesterol (P = 0.08), changes
in the beneficial direction were greater on the high-fat
dietary pattern. Similar effects have been reported in a
non-cancer survivor population [49].
Breast-cancer patients have elevated cardiovascular
disease risk depending on their treatment; in patients
who receive anthrocyclins, a well-known potential exists
to induce cardiomyopathies with associated problems
[28]. Because it has been reported that high dietary con-
centrations of lipid promote the metabolic processes
that predispose to atherogenesis [25], safety monitoring
focused on circulating lipids that are recognized indica-
tors of cardiovascular disease risk is indicated. From the
observed changes in lipid profiles, two findings are
particularly noteworthy: (a) weight loss resulted in pro-
tective changes in the blood-lipid profiles, and (b) the
beneficial changes occurred irrespective of dietary pat-
tern. Because patient motivation is critical to successful
weight loss, and dietary preferences can be strong deter-
minants of adherence to a dietary plan, these findings
indicate that from a safety perspective relative to cardio-
vascular disease risk, determined by the type of blood
chemistries that attending physicians routinely have at
their disposal, it is acceptable for patients to follow a
dietary plan that meets their personal preferences during
weight loss, provided that it is nutritionally balanced.
Deeper inspection of the data shown in Table 4 indi-
cates more-subtle differences of dietary pattern on spe-
cific lipid indicators; effects were associated with
classification by whether weight loss was below or above
the mean.
The findings on lipid metabolites also have implica-
tions related to mechanisms of tumor progression
[50-54]. Although controversial, it has been reported in
both epidemiologic studies and laboratory investigations
that circulating levels of cholesterol, LDL-cholesterol,
and HDL-cholesterol play a role in tumor development,
tumor growth, and/or tumor aggressiveness, as summar-
ized in [48]. In this regard, if causality is ultimately
demonstrated, activities that limit availability of choles-
terol and reduce the activity associated with cholesterol
lipoprotein function would be considered beneficial.
Hence, in view of the data shown in Table 4, our find-
ings provide yet another mechanistic lead about the role
Table 4 Estimated slope from repeated-measures models of biomarkers by time and diet group




















































































































Values are expressed as slope ± SEE. (n = 44 Control; n = 50 Low Fat; n = 48 Low Carb) aValues within a column are statistically different from 0 at the 0.05 level.
WL, weight loss; SEE, standard error of the estimate. bThe selected contrasts address the question of which slopes are different from each other. cAdjusted P by
using the Hochberg step-up procedure to control the family-wise type I error rate within each marker. Carb, carbohydrate; CHOL, cholesterol; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; TRIG, triglyceride.
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of weight loss in promoting long-term survival after
treatment for breast cancer.
Limitations
Participants in this study were breast-cancer survivors
from one clinical practice, which may limit the general-
izability of the findings. We caution about the overinter-
pretation of these findings because the data were not
the primary measures for the trial; we elected to control
the type I error rate for the four comparisons done
within each marker but not across markers. Another
potential limitation of the study was that assignment to
dietary arm was not randomized; however, this is likely
to have translational value because individuals generally
self-select dietary approaches that they prefer by which
to lose weight.
Conclusions
The work reported herein is a component of a sys-
tematic effort to increase awareness about the impor-
tant contribution that weight loss and weight
maintenance in the healthy range can offer to promote
the long-term survival of breast-cancer patients. Given
the prevalence of overweight and obesity, not only in
the U.S. population as a whole, but also globally, and
that a majority of women who have undergone treat-
ment for breast cancer are overweight or obese, the
importance of this issue is emphasized. The results of
this investigation address a safety aspect of a question
commonly asked of physicians by their patients: does it
matter what dietary plan I choose to lose weight?
Because an individual’s dietary preferences can affect
dietary adherence and weight-loss success, the lack of
evidence of a negative effect of dietary pattern on car-
diovascular risk is an important consideration in the
development of clinical practice guidelines for physi-
cians who recommend that their patients lose weight.
Once weight is lost, questions similar to those being
asked in this study must be addressed in the context
of long-term weight maintenance.
Abbreviations
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